Eric M. Yoshida

20.2k citations

383 papers · 8.8k indexed · 2 hit papers · h-index 46

Impact in

Hepatology top 0.05%
- Hepatitis C virus research
- Liver Disease and Transplantation
- Liver Diseases and Immunity
Epidemiology top 0.2%
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies

Papers in

Hepatology 262
- Hepatitis C virus research 146
- Liver Disease and Transplantation 89
- Liver Diseases and Immunity 46
Transplantation 26
- Renal Transplantation Outcomes and Treatments 26

Co-authors: Charles H. Scudamore Siegfried R. Erb Janakie Singham Urs P. Steinbrecher Vincent G. Bain Nilufar Partovi Hin Hin Ko Mel Krajden
Journals: Journal of Hepatology (23 papers)Canadian Journal of Gastroenterology and Hepatology (17 papers)Liver International (9 papers)Transplantation (9 papers)Journal of Clinical Gastroenterology (7 papers)
Partner nations: Canada United States United Kingdom

In The Last Decade

Eric M. Yoshida

361 papers receiving 8.5k citations

Hit Papers

align trajectories log scale

Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment 2017 · 271 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 New England Journal of Medicine
2014 New England Journal of Medicine

Peers

Countries citing papers authored by Eric M. Yoshida

Since Specialization

Citations

This map shows the geographic impact of Eric M. Yoshida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric M. Yoshida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric M. Yoshida more than expected).

Fields of papers citing papers by Eric M. Yoshida

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric M. Yoshida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric M. Yoshida. The network helps show where Eric M. Yoshida may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Eric M. Yoshida, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric M. Yoshida Line = papers co-authored together Eric M. Yoshida links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A306 A CASE OF SCLEROSING CHOLANGITIS AS A COMPLICATION OF CAR-T THERAPY Journal of the Canadian Association of Gastroenterology ·Bixiao Zhao, YU Min-li, Alex L. Huang, 烈史塚本, Daljeet Chahal, Eric M. Yoshida	2024	0
2	Methods and validation of velacur determined fat fraction in patients with MASLD SHILAP Revista de lepidopterología ·M.E. Schaefer, Julio Lobo, Caitlin Schneider, Samuel Klein, Gordon I. Smith, Rohit Loomba, Alnoor Ramji, Tarek Hassanein, Eric M. Yoshida, Оlena Aksyonova, Michael P. Curry, Nezam H. Afdhal	2024	1
3	Impact of COVID‐19 pandemic on hepatocellular carcinoma surveillance in British Columbia, Canada: An interrupted time series study Journal of Viral Hepatitis ·Jean Damascène Makuza, Stanley Wong, Richard L. Morrow, Mawuena Binka, Maryam Darvishian, Dahn Jeong, Prince Adu, Кетова Г. Г., Amanda Yu, Héctor Alexander Velásquez García, Sofia Bartlett, Eric M. Yoshida, Alnoor Ramji, Mel Krajden, Naveed Z. Janjua	2024	2
4	Association of hepatitis B virus treatment with all-cause and liver-related mortality among individuals with HBV and cirrhosis: a population-based cohort study The Lancet Regional Health - Americas ·Jean Damascène Makuza, Dahn Jeong, Stanley Wong, Mawuena Binka, Prince Adu, Héctor Alexander Velásquez García, Richard L. Morrow, Кетова Г. Г., Amanda Yu, Maria Alvarez, Sofia Bartlett, Hin Hin Ko, Eric M. Yoshida, Alnoor Ramji, Mel Krajden, Naveed Z. Janjua	2024	2
5	Impact of Hepatitis B Virus Infection, Non-alcoholic Fatty Liver Disease, and Hepatitis C Virus Co-infection on Liver-Related Death among People Tested for Hepatitis B Virus in British Columbia: Results from a Large Longitudinal Population-Based Cohort Study Viruses ·Jean Damascène Makuza, Dahn Jeong, Mawuena Binka, Prince Adu, Кетова Г. Г., Amanda Yu, Héctor Alexander Velásquez García, Maria Alvarez, Stanley Wong, Sofia Bartlett, Mohammad Ehsanul Karim, Eric M. Yoshida, Alnoor Ramji, Mel Krajden, Naveed Z. Janjua	2022	5
6	Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study Open Forum Infectious Diseases ·James Wilton, Stanley Wong, Amanda Yu, Alnoor Ramji, Darrel Cook, Zahid A Butt, Maria Alvarez, Mawuena Binka, Maryam Darvishian, Dahn Jeong, Sofia Bartlett, Margo Pearce, Prince Adu, Eric M. Yoshida, Mel Krajden, Naveed Z. Janjua	2020	26
7	The impact of SVR from direct‐acting antiviral‐ and interferon‐based treatments for HCV on hepatocellular carcinoma risk Journal of Viral Hepatitis ·Naveed Z. Janjua, Stanley Wong, Maryam Darvishian, Zahid A Butt, Amanda Yu, Mawuena Binka, Maria Alvarez, Ryan Woods, Eric M. Yoshida, Alnoor Ramji, Jordan J. Feld, Mel Krajden	2020	37
8	Public awareness of acetaminophen and risks of drug induced liver injury: Results of a large outpatient clinic survey PLoS ONE ·Robert A. Mitchell, Sahaj Rathi, Stephan Illing, 賢三若江, Trana Hussaini, Eric M. Yoshida	2020	18
9	Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk Journal of Viral Hepatitis ·Maryam Darvishian, Naveed Z. Janjua, Mei Chong, Darrel Cook, Hasina Samji, Zahid A Butt, Amanda Yu, Maria Alvarez, Eric M. Yoshida, Alnoor Ramji, Jason Wong, Ryan Woods, Mark Tyndall, Mel Krajden	2018	8
10	Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting PLoS ONE ·Hla‐Hla Thein, Yao Qiao, Ahmad Zaheen, Nathaniel Jembere, Gonzalo Sapisochín, Kelvin Chan, Eric M. Yoshida, Craig C. Earle	2017	21
11	Cost‐effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person‐level data in a Canadian setting Cancer Medicine ·Hla‐Hla Thein, Wanrudee Isaranuwatchai, Yao Qiao, Kenny K. Wong, Gonzalo Sapisochín, Kelvin Chan, Eric M. Yoshida, Craig C. Earle	2017	17
12	Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: A systematic review Journal of Clinical and Translational Hepatology ·Jeremy Maxwell Sharp, Trana Hussaini, Е.В. Ерофеев, Dell, Siegfried R. Erb, Nilufar Partovi, Eric M. Yoshida	2016	24
13	Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990–2009 PLoS ONE ·Nathaniel Jembere, Michael A. Campitelli, Morris Sherman, Jordan J. Feld, Wendy Lou, Stuart Peacock, Eric M. Yoshida, Murray Krahn, Craig C. Earle, Hla‐Hla Thein	2012	40
14	Clinical Vignette: Splenic Abscesses. Milana Vranešević, Kees Vermeer, S. Morad Hameed, Alison Harris, Pacharawan Pathmanand, Eric M. Yoshida	2010	1
15	Sustained Responders Have Better Quality of Life and Productivity Compared With Treatment Failures Long After Antiviral Therapy for Hepatitis C The American Journal of Gastroenterology ·Ava John‐Baptiste, George Tomlinson, Diego Basilio, Mel Krajden, E. Jenny Heathcote, Audrey Laporte, Eric M. Yoshida, Frank Anderson, Murray Krahn	2009	72
16	Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. PubMed ·Vince Bacarac, Kiran Assi, David Owen, David G. Huntsman, Stephen W. Chung, Charles H. Scudamore, Eric M. Yoshida, Baljinder Salh	2008	9
17	[9] COMPARABLE ANTIVIRAL RESPONSE RATES WITH ALBUMIN INTERFERON ALFA-2B DOSED AT Q2W OR Q4W INTERVALS IN NAIVE SUBJECTS WITH GENOTYPE 2 OR 3 CHRONIC HEPATITIS C Journal of Hepatology ·Vincent G. Bain, Boris Uspenskii, K. Kaita, Eric M. Yoshida, Mark G. Swain, R.J. Bailey, Avidan U. Neumann, A.I. Bondarev, John G. McHutchison, Erik Pulkstenis, Mani Subramanian	2007	3
18	[127] Phil PROOF OF CONCEPT STUDY OF CELGOSIVIR IN COMBINATION WITH PEGINTERFERON o-2b AND RIBAVIRIN IN CHRONIC HEPATITIS C GENOTYPE-1 NON-RESPONDER PATIENTS Journal of Hepatology ·K. Kaita, Eric M. Yoshida, Derek Kunimoto, Frank Anderson, Amanda L. Hollatz, Boris Uspenskii, Linda Scully, Kevork Peltekian, Robert Enns, Francisco Díaz‐Mitoma, Fei Linfeng, Lawrence Worobetz, Héctor Díaz, Harini Rajaram	2007	19
19	[615] MANAGEMENT OF CHRONIC HEPATITIS C IN A DIVERSE POPULATION WITH PEGINTERFERON tt-2a AND RIBAVIRIN: FINAL RESULTS OF THE CANADIAN PEGASYS EXPANDED ACCESS PROGRAM (EAP) Journal of Hepatology ·Marc Deschênes, Eric M. Yoshida, Kevork Peltekian, Curtis Cooper, Vincent G. Bain, Mel Krajden, Morris Sherman, 김의남, Robert Balshaw, Boris Uspenskii	2007	2
20	Transplant immunosuppressive agents in non‐transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus Liver International ·E. Trapanese, Alnoor Ramji, Vincent G. Bain, Mang Ma, Paul J. Marotta, Cameron N. Ghent, Leslie Lilly, E. Jenny Heathcote, Marc Deschênes, Samuel S. Lee, Urs P. Steinbrecher, Eric M. Yoshida	2005	87

About Eric M. Yoshida

Eric M. Yoshida is a scholar working on Hepatology, Transplantation, Epidemiology, Surgery and Infectious Diseases, having authored 383 papers that have together received 8.8k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (147 papers), Hepatitis C virus research (146 papers), Hepatitis B Virus Studies (94 papers), Liver Disease and Transplantation (89 papers), Organ Transplantation Techniques and Outcomes (49 papers), Liver Diseases and Immunity (46 papers), Renal Transplantation Outcomes and Treatments (26 papers) and HIV/AIDS drug development and treatment (24 papers). The work is most often cited by research in Hepatology (5.7k citations), Epidemiology (5.4k citations), Transplantation (361 citations), Infectious Diseases (1.1k citations) and Surgery (1.8k citations). Eric M. Yoshida has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Charles H. Scudamore, Siegfried R. Erb, Janakie Singham, Urs P. Steinbrecher, Vincent G. Bain, Nilufar Partovi, Hin Hin Ko, Mel Krajden, Trana Hussaini and Marc Deschênes. Their work appears in journals such as Journal of Hepatology, Canadian Journal of Gastroenterology and Hepatology, Liver International, Transplantation and Journal of Clinical Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact